Compare ZETA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZETA | WGS |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 2021 | N/A |
| Metric | ZETA | WGS |
|---|---|---|
| Price | $20.45 | $108.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $26.58 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 8.6M | 554.5K |
| Earning Date | 02-24-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $1,224,703,000.00 | $402,190,000.00 |
| Revenue This Year | $30.65 | $41.17 |
| Revenue Next Year | $32.27 | $23.53 |
| P/E Ratio | ★ N/A | $1,499.76 |
| Revenue Growth | 35.87 | ★ 50.50 |
| 52 Week Low | $10.69 | $55.17 |
| 52 Week High | $26.60 | $170.87 |
| Indicator | ZETA | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 26.62 |
| Support Level | $22.63 | $103.01 |
| Resistance Level | $24.90 | $113.24 |
| Average True Range (ATR) | 1.18 | 8.17 |
| MACD | -0.14 | -2.74 |
| Stochastic Oscillator | 18.82 | 13.21 |
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.